title: Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer.
abstract: Numerous lines of evidence suggest that the polypeptide hormone prolactin (PRL) may contribute to breast and prostate tumorigenesis through its interactions with the prolactin receptor (PRLR). Here, we describe the biologic properties of LFA102, a humanized neutralizing monoclonal antibody directed against the extracellular domain of PRLR. This antibody was found to effectively antagonize PRL-induced signaling in breast cancer cells in vitro and in vivo and to block PRL-induced proliferation in numerous cell line models, including examples of autocrine/paracrine PRL activity. A single administration of LFA102 resulted in regression of PRL-dependent Nb2-11 tumor xenografts and significantly prolonged time to progression. Finally, LFA102 treatment significantly inhibited PRLR signaling as well as tumor growth in a carcinogen-induced, estrogen receptor-positive rat mammary cancer model as a monotherapy and enhanced the efficacy of the aromatase inhibitor letrozole when administered in combination. The biologic properties of LFA102, elucidated by the preclinical studies presented here, suggest that this antibody has the potential to be a first-in-class, effective therapeutic for the treatment of PRL-dependent cancers.
authors.affiliation: Novartis Institutes for BioMedical Research, Emeryville, CA 94608, USA. Jason.damiano@novartis.com
authors.forename: Jason S
authors.initials: JS
authors.lastname: Damiano
authors.forename: Katherine G
authors.initials: KG
authors.lastname: Rendahl
authors.forename: Christopher
authors.initials: C
authors.lastname: Karim
authors.forename: Millicent G
authors.initials: MG
authors.lastname: Embry
authors.forename: Majid
authors.initials: M
authors.lastname: Ghoddusi
authors.forename: Jocelyn
authors.initials: J
authors.lastname: Holash
authors.forename: Abdallah
authors.initials: A
authors.lastname: Fanidi
authors.forename: Tinya J
authors.initials: TJ
authors.lastname: Abrams
authors.forename: Judith A
authors.initials: JA
authors.lastname: Abraham
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D049109:Cell Proliferation / Q000187:drug effects; D005260:Female; D006801:Humans; D061986:MCF-7 Cells; D051379:Mice; D058990:Molecular Targeted Therapy; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011388:Prolactin / Q000378:metabolism; D051381:Rats; D011981:Receptors, Prolactin / Q000037:antagonists & inhibitors / Q000276:immunology*; D023041:Xenograft Model Antitumor Assays
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C583731:LFA102 monoclonal antibody; D011981:Receptors, Prolactin; D011388:Prolactin